The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab
Hidekazu Kuramochi, Takeshi Yamada, Yoichiro Yoshida, Akihisa Matsuda, Hirohiko Kamiyama, Chihiro Kosugi, Keiichiro Ishibashi, A. Fukazawa, Keisuke Ihara, Hiromichi Sonoda, Kazuhiko Yoshimatsu, Hiroshi Yoshida, Suguru Hasegawa, Kazuhiro Sakamoto, Hideyuki Ishida, Keiji Koda, On behalf of the TAS CC3 Study Group
Abstract
BACKGROUND/AIM: -line treatment. PATIENTS AND METHODS: We investigated the predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS by a post-hoc analysis. RESULTS: Receiver operating characteristic curve analyses of the 3 inflammation-based scores versus DC showed the best predictive performance for LMR, followed by NLR and PLR. The high-LMR group had a significantly higher DC rate than the low group (87.5 vs. 43.8%). The high-LMR group showed significantly longer survival than the low group (4.9 vs. 2.3 m for median PFS) (21.0 vs. 6.1 m for median OS). CONCLUSION: The pre-treatment LMR is a valid predictive and prognostic biomarker for mCRC patients undergoing TAS-102 and bevacizumab treatment.